FI
GALT icon

FormulaFolio Investments’s Galectin Therapeutics GALT Stock Holding History

FormulaFolio Investments’s Portfolio GALT Stock Details GALT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-12,710
Closed -$28K – 586
2020
Q4 		$28K Buy
+12,710
New +$33.4K ﹤0.01% 661

Other funds holding GALT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
GWM
Geneos Wealth Management Englewood, Colorado $4.31B AUM 18.36% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
CCB
Cutter & Co Brokerage Ballwin, Missouri $423M AUM 15.02% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

FormulaFolio Investments's GALT Position: Q1 2021 in Review

FormulaFolio Investments sold out of Galectin Therapeutics (GALT) in Q1 2021, closing a stake of 12,710 shares — an estimated $28K sold.

FormulaFolio Investments first reported a position in GALT in Q4 2020 and held it in 1 quarter. The position peaked at $28K in Q4 2020. 75 funds tracked by Wall St. Rank hold GALT as of Q1 2021.

  • FormulaFolio Investments reported no remaining Galectin Therapeutics position as of Q1 2021 after selling out during the quarter.
  • FormulaFolio Investments sold 12,710 Galectin Therapeutics shares in Q1 2021, an estimated $28K.
  • FormulaFolio Investments first reported a position in Galectin Therapeutics in Q4 2020 and held it in 1 quarter.
  • FormulaFolio Investments's Galectin Therapeutics position peaked at $28K in Q4 2020.
  • 75 funds tracked by Wall St. Rank held Galectin Therapeutics as of Q1 2021.

Based on FormulaFolio Investments's 13F filing for Q1 2021, filed 28 May 2021.